Is telehealth allowed to prescribe Strattera in California?

Understanding Telehealth Options for ADHD Non-Stimulant Medications

If you’re considering treatment for ADHD through telehealth, understanding what medications can be prescribed virtually is essential. While stimulant medications like Adderall and Ritalin face stricter regulations, non-stimulant options like Strattera (atomoxetine) have fewer restrictions. This comprehensive guide explains current telehealth prescribing rules for ADHD non-stimulants, with state-specific details to help you navigate your treatment options.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

The Federal Landscape: Non-Stimulants and Telehealth

Non-stimulant ADHD medications like Strattera have a significant advantage in telehealth: they are not controlled substances. Unlike stimulants (which are Schedule II controlled substances), medications like Strattera:

• Are not regulated under the DEA’s Controlled Substances Act
• Do not require special DEA prescribing waivers
• Are not subject to the Ryan Haight Act’s in-person examination requirements
• Can generally be prescribed through telehealth in all states

This distinction is important because while stimulant medications have been temporarily allowed via telehealth under COVID-19 emergency rules (currently extended through December 31, 2025), non-stimulants like Strattera have always been eligible for telehealth prescription without special federal exemptions.

Why Consider Non-Stimulant ADHD Medication?

Non-stimulant medications offer several advantages for telehealth patients:

• No risk of dependency or abuse: Strattera and other non-stimulants aren’t habit-forming
• Fewer prescription restrictions: Can be prescribed with refills (unlike Schedule II stimulants)
• Longer-lasting coverage: Works 24 hours a day (not just during ‘active’ hours like stimulants)
• Fewer side effects: May cause less insomnia, appetite suppression, or cardiovascular effects
• Fewer legal barriers: Easier to access through telehealth with fewer regulatory hurdles

While non-stimulants typically take longer to show their full effects (often 4-6 weeks versus the immediate impact of stimulants), they can be equally effective for many patients with ADHD.

State-by-State Telehealth Rules for Non-Stimulants

While federal law doesn’t restrict telehealth prescribing of non-stimulants, state laws can add their own requirements. Here’s how key states handle non-stimulant ADHD medications via telehealth:

California

• Telehealth Allowed: Yes, fully permitted for ADHD treatment
• In-Person Requirement: None for non-stimulants
• Prescription Monitoring: Not required for non-controlled medications
• Provider Types: MDs, DOs, NPs (independent practice), and PAs (collaborative) can all prescribe

California has embraced telehealth, with a 2023 law strengthening telehealth practice definitions. Providers can establish a doctor-patient relationship entirely through telehealth for non-controlled medications.

New York

• Telehealth Allowed: Yes, with robust telehealth infrastructure
• In-Person Requirement: None for non-stimulants (only required for controlled substances)
• Prescription Monitoring: Not required for non-controlled medications
• Provider Types: MDs, DOs, and NPs with independent practice can prescribe

New York implemented stricter rules for controlled substances in 2025, requiring in-person evaluation before prescribing controlled medications via telehealth. However, these restrictions don’t apply to non-stimulant options like Strattera.

Florida

• Telehealth Allowed: Yes, with clear statutory support
• In-Person Requirement: None for non-stimulants
• Prescription Monitoring: Not required for non-controlled medications
• Provider Types: MDs, DOs, NPs and PAs (under collaborative agreement) can prescribe

Florida requires video-based telehealth (audio-only is insufficient) for establishing a provider-patient relationship, but otherwise permits telehealth prescribing of non-controlled medications without special restrictions.

Texas

• Telehealth Allowed: Yes, especially for mental health treatment
• In-Person Requirement: None for non-stimulants
• Prescription Monitoring: Not required for non-controlled medications
• Provider Types: MDs, DOs, NPs and PAs (under physician delegation) can prescribe

Texas has been progressive with telehealth for mental healthcare, allowing providers to establish relationships and prescribe non-controlled medications through virtual visits. The state’s 12-month chronic pain rule doesn’t apply to ADHD treatment.

Alabama

• Telehealth Allowed: Yes, but with some of the strictest overall telehealth rules
• In-Person Requirement: Annual in-person exam required after 4 telehealth visits for ongoing care (though mental health services are exempt)
• Prescription Monitoring: Not required for non-controlled medications
• Provider Types: MDs, DOs, and NPs/PAs with appropriate credentials can prescribe

Alabama has stricter telehealth regulations generally, but ADHD treatment may qualify under the mental health exemption from periodic in-person requirements.

Other Notable States:

• New Hampshire: Recently liberalized telehealth rules, removing prior in-person requirements
• Georgia: Permits telehealth without special requirements for non-stimulants
• Pennsylvania: Has permanent telehealth prescribing laws supporting non-controlled medications

What to Expect in a Telehealth ADHD Evaluation

When seeking non-stimulant ADHD treatment via telehealth, you’ll typically experience:

1. Comprehensive assessment: Expect a thorough evaluation using standardized ADHD criteria, not a quick prescription
2. Video-based visit: Most states require audiovisual technology (not just a phone call)
3. Medical history review: Your provider will collect detailed information about previous treatments and conditions
4. Medication options discussion: The provider will explain why a non-stimulant might be appropriate
5. Treatment planning: Beyond medication, they should discuss behavioral strategies and monitoring
6. Follow-up schedule: Regular check-ins to monitor effectiveness and side effects

A legitimate telehealth ADHD evaluation will be comprehensive and take time—quick ‘prescription mill’ services should raise red flags.

Non-Stimulant Medication Profile: Strattera (Atomoxetine)

Strattera is the most commonly prescribed non-stimulant medication for ADHD via telehealth:

Other non-stimulant options that can be prescribed via telehealth include Qelbree (viloxazine), Intuniv/Tenex (guanfacine), and Kapvay (clonidine), each with their own profile of benefits and side effects.

Telehealth Provider Options for Non-Stimulant ADHD Medication

When seeking telehealth care for ADHD with non-stimulant treatment, consider these provider options:

Specialized ADHD Telehealth Platforms

Services like Klarity Health connect patients with licensed mental health providers specifically trained in ADHD evaluation and treatment. Klarity Health offers several advantages for those seeking non-stimulant options:

• Transparent pricing with both insurance and cash-pay options
• Providers available in most states
• Comprehensive ADHD assessments that meet diagnostic standards
• Regular follow-up to monitor treatment effectiveness

Psychiatric Telehealth Services

Many general psychiatric telehealth platforms offer ADHD treatment, including non-stimulant options.

Primary Care Telehealth

Some primary care telehealth services can manage straightforward ADHD cases, though they may have less specialized expertise than psychiatric providers.

When choosing a provider, look for:

• Clear information about their ADHD assessment process
• Licensed providers in your state
• Transparent pricing an

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment